The Pathology Core enables City of Hope Cancer Center investigators to directly study protein and genetic material from human tumors and normal tissues to validate specific hypotheses generated from pre-clinical studies. It also provides analyses of specific protein expression in tumor and normal tissues to enable scientists to discern the distribution patterns of these proteins in specific tissue or cell types. The Pathology Core provides services primarily in the areas of expertise of the Department of Anatomic Pathology. They fall into the following areas: (1) performance and assistance in the routine histological processing of tissues, including paraffin embedding, sectioning, and hematoxylin and eosin (H&E) staining of human tissue, animal tissue, and preparations from cell lines, as well as specialized histological services such as preparation of multi-tumor blocks or tissue arrays to the specifications of the researchers;(2) performance and interpretation of immunohistochemistry for the detection of proteins in normal and tumor tissues, including evaluation and technical development of new antibodies as well as the technology to detect multiple antigens in the same histological section;(3) performance and assistance in Laser Capture Microdissection from paraffin or frozen sections to obtain enrichment of specific cell types, including isolation of malignant cells, for the analysis of proteins, RNA and/or DNA content;(4) assistance in preparing formalin-fixed tissues for conventional PCR and genome sequencing;and (5) consultation services to Cancer Center investigators. Expertise in the pathological basis of disease, the histological manifestations of disease, and the use of human tissues for studying disease states is available for the preparation of grants and papers and in the design of experiments.
The overall goal of the Pathology Core facility is to facilitate research from Cancer Center investigators in animal models and human malignancies by providing access to pathology services and archiving tumors and normal tissues collected from excess surgical materials. The tissue tumor bank includes more than 14,000 samples accumulated over 30 years. This goal enhances the Cancer Center's mission of developing innovative therapeutic strategies in the battle against cancer.
|Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33|
|Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68|
|Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41|
|Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9|
|Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85|
|Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124|
|Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70|
|Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209|
|Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53|
|Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70|
Showing the most recent 10 out of 912 publications